Цефутил

Quick links to important sections

Цефутил

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Цефутил

Property Description
Active ingredient Cefuroxime
Form Tablet, oral suspension, powder for injection
Pharmacological class Second-generation cephalosporin antibiotic
Common purpose Systemic treatment of bacterial infections
Origin Semisynthetic

Цефутил: Identity and Role as a beta-Lactam Antibiotic

Цефутил is the trade name for a pharmaceutical product whose active substance is Cefuroxime, classified as a semisynthetic beta-lactam antibiotic. Its general purpose is the systemic elimination of susceptible bacterial infections. Cefuroxime belongs to the second-generation cephalosporin class, which is structurally designed to provide a broad spectrum of activity against various bacterial species.

The drug is an established therapy, clinically recognized for its effectiveness in treating common community-acquired infections. Cefuroxime is included on model lists of essential medicines for its recognized public health significance.


The Semisynthetic Composition and Available Forms

Цефутил is a single-ingredient product, featuring Cefuroxime as the sole active compound. It is supplied in two primary chemical forms to enable different routes of administration: Cefuroxime axetil, an inactive prodrug for the oral route, and Cefuroxime sodium, a salt used for injection. The product is often utilized in pediatric patients due to the availability of the oral suspension form.

These preparations are available in several dosage forms, including film-coated tablets, granules for preparing an oral suspension, and a powder for injection for parenteral administration. The oral form (axetil) is absorbed in the gastrointestinal tract and then chemically converted by the body into the active Cefuroxime.


How Cefuroxime Works Against Bacteria

Cefuroxime acts as a bactericidal agent, meaning it actively kills susceptible bacteria by directly interfering with their structural integrity. Its core mechanism involves binding to critical enzymes within the bacterial cell membrane, which prevents the completion of the bacterial cell wall synthesis. Furthermore, the chemical structure of Cefuroxime provides stability against certain beta-lactamase enzymes produced by bacteria, supporting its effectiveness against microbes that have developed resistance to some older antibiotics.

Regulatory References

  1. World Health Organization (WHO)
  2. Model Lists of Essential Medicines

What side effects are possible with Цефутил?

Possible side effects and safety information

Cefuroxime has an officially documented safety profile structured around the body systems affected and the frequency of occurrence, as defined in government regulatory documents.

Frequency and System-Organ Classes

The most frequently reported effects, classified as common in official labeling, involve Gastrointestinal Disorders, such as diarrhea and nausea, and Nervous System Disorders, including headache and dizziness. Effects on the Blood and Lymphatic System, such as eosinophilia (common) and a positive Coombs test (uncommon), are also noted.

Classification Examples of Documented Effects
Common Headache, Dizziness, Diarrhea, Nausea, Eosinophilia, Transient increases in liver enzymes
Uncommon Vomiting, Abdominal pain, Skin rash, Decreased hemoglobin, Positive Coombs test

Serious Adverse Reactions and Restrictions

Regulatory documents list severe events that, while rare, are clinically significant. These include immediate, severe hypersensitivity reactions such as anaphylaxis, and severe forms of colitis known as Clostridioides difficile-associated diarrhea (CDAD), which may occur during or after treatment. Rare, serious skin reactions (e.g., Stevens-Johnson syndrome) are also documented.

The medicine is formally contraindicated in individuals with a known hypersensitivity to cephalosporin antibiotics or a history of immediate, severe allergy to any other beta-lactam antibacterial agent (e.g., penicillins).

Population-Specific Notes

The drug is eliminated primarily via the kidneys, meaning official guidance recommends dose adjustment for patients with marked renal impairment. Regarding lactation, Cefuroxime is excreted in human milk, and a potential for diarrhea or fungal infection in the infant is acknowledged in regulatory safety statements.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documents define the official overdose profile for Cefuroxime primarily by its potential for Central Nervous System (CNS) toxicity.


Documented Overdose Manifestations

Overdose resulting in high drug serum levels is officially documented to present with signs of cerebral irritancy and convulsions (seizures). In severe cases, these symptoms may progress to encephalopathy and coma, which are classified as severe CNS toxicity and neurological sequelae.


Emergency Response and Management

Immediate medical attention is required upon confirmed or suspected overdose. Regulators state that emergency services must be contacted immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

For management, symptomatic and supportive treatment is the documented approach. Official prescribing information states that procedures such as haemodialysis and peritoneal dialysis are methods to effectively reduce high Cefuroxime serum levels. It is officially noted that no specific antidote is known for Cefuroxime overdose.


Population-Specific Consideration

The official labeling explicitly notes that patients with renal impairment are at increased risk for developing overdose symptoms if their dosage is not appropriately reduced. This is due to the drug's impaired clearance in this population, which can lead to excessive systemic accumulation.

Therapeutic Uses of Цефутил

What Цефутил Treats: Main Uses and Benefits

Цефутил is commonly used in conditions characterized by periods of heightened symptoms across several domains of infection. The medication is considered relevant for easing symptoms linked to infections of the respiratory tract (like tonsillitis and bacterial sinusitis), the middle ear (acute otitis media), skin and soft tissue infections, and urinary tract infections (UTIs). It is also applied in addressing specific scenarios, such as managing the early, symptomatic rash of Lyme disease.

The medication is applied in addressing symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort, fever, and inflammatory or irritative states. In more challenging clinical settings, the injectable form may be part of symptomatic management for severe, systemic conditions like septicemia.

“Applied in scenarios where additional management of discomfort is required, treatment supports the patient during episodes of heightened discomfort.”

The medication provides support that contributes to easing the overall symptom load associated with these acute or disruptive episodes.


Quick Fact: Support for Symptoms related to Physical Discomfort and Systemic Imbalance

Regulatory References

  1. FDA Drug Label via DailyMed

Eligibility and Restrictions for Use

Who can and cannot use Цефутил?

The eligibility for using Цефутил (Cefuroxime) is strictly defined by regulatory authorities based on age, allergies, and specific health conditions.

Contraindications (Must Not Use)

  • Known hypersensitivity to Cefuroxime, any cephalosporin antibiotic, or a history of severe allergy to penicillins or other beta-lactam antibacterial agents.

Age and Population Eligibility

  • Approved Use: Use is established for adults and adolescents (ge 13 years) and for pediatric patients (ge 3 months to 12 years), primarily via oral suspension.
  • Not Established: Safety and effectiveness have not been established in infants under 3 months of age.
  • Conditional Use: Dosage adjustment is required for patients with markedly impaired renal function (Creatinine Clearance < 30 mL/min). The oral suspension is restricted for patients with Phenylketonuria (PKU) due to the phenylalanine content.

Pregnancy and Lactation

  • Pregnancy: Use is generally considered if the benefit outweighs the risk, as data have not established a drug-associated risk of major birth defects.
  • Lactation: Cefuroxime is excreted in human milk at low levels, making use generally permissible with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope and Restrictions

The regulatory profile for Cefuroxime primarily focuses on interactions that modify drug exposure and specific pharmacodynamic effects. Co-administration with Probenecid is not recommended as this agent inhibits renal tubular secretion, significantly increasing the systemic exposure and concentration of Cefuroxime. Drugs that reduce gastric acidity, including H2 antagonists and Proton Pump Inhibitors (PPIs), must be avoided because they substantially lower the oral bioavailability of Cefuroxime axetil. Short-acting antacids require administration to be separated by at least 1 hour before or 2 hours after Cefuroxime axetil. Food is an essential context constraint, as the absorption of the oral form is enhanced with food.

Pharmacodynamic and Test Interactions

Pharmacodynamic interactions include the potential for reduced efficacy of combined oral contraceptives due to documented effects on gut flora. Concomitant use with oral anticoagulants requires monitoring due to the potential for a fall in prothrombin activity. Furthermore, co-administration with other agents suspected of adversely affecting renal function, such as Aminoglycosides or Potent Diuretics, requires caution due to a reported increased risk of nephrotoxicity. The drug officially interferes with specific laboratory procedures, causing a false-positive direct Coombs test and false results in certain copper reduction tests for urine glucose.

Mechanism of Action

How Цефутил Works

Цефутил (Cefuroxime) acts as a bactericidal agent through the interruption of processes required for bacterial cell growth and structure.


Molecular Targeting of Cell Wall Enzymes

The drug functions by specifically targeting and inhibiting Penicillin-Binding Proteins (PBPs), a group of enzymes critical to bacterial cell structure. Cefuroxime forms an irreversible covalent bond with these PBPs, primarily the transpeptidases, immediately halting their ability to function. This molecular interaction results in the cessation of the cell wall's rigid scaffold assembly.


Cascade of Cell Wall Breakdown

By blocking the transpeptidases, Cefuroxime prevents the necessary peptidoglycan cross-linking required for a stable cell wall. The structurally compromised bacterial cell is unable to withstand internal osmotic pressure, triggering lysis (rupture) of the cell. This action constitutes the bactericidal effect of the mechanism.


️ Structural Stability Against Bacterial Enzymes

Cefuroxime's chemical structure provides stability against hydrolysis by specific beta-lactamase enzymes produced by some bacteria. This stability allows the primary PBP-inhibiting mechanism to function against certain organisms that express these enzymes.

Dosage and Administration Information

Official Administration Guidelines for Cefuroxime

Administration of Cefuroxime (Цефутил) is based on specific instructions to ensure the proper use of its various forms. The medication is administered via the oral route (as film-coated tablets or an oral suspension) or the parenteral route (intravenous (IV) or intramuscular (IM) injection).

Standard Dosing Patterns

Administration Route Typical Adult Dosing Regimen Frequency Pattern
Oral (Tablets) 250 mg or 500 mg per dose Twice daily (every 12 hours)
Parenteral (IV/IM) 750 mg or 1.5 g per dose Every 8 hours (up to every 6 hours in severe cases)

The standard duration of treatment typically ranges from 7 to 10 days for most conditions. However, the course for treating early Lyme disease is extended to 20 days.

Contextual Intake Rules and Adjustments

The method of intake is crucial for absorption. While the oral tablets may be taken with or without food, the oral suspension form must be taken with food to maximize the bioavailability of the active drug. The tablet form must be swallowed whole and should not be crushed or chewed. Furthermore, the dosing interval is prolonged for adult patients with significant renal impairment, specifically those with a creatinine clearance less than 30 mL/min. The oral tablet and suspension formulations are not bioequivalent and should not be substituted on a milligram-for-milligram basis.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Цефутил (Cefuroxime)


Evidence for Use in Respiratory Tract Infections (Sinusitis, Tonsillitis, and Pharyngitis)

Research on bacterial infections of the respiratory tract, such as sinusitis and tonsillitis, has primarily relied on short-term randomized controlled trials (RCTs) that evaluated Cefuroxime. These studies often compared Cefuroxime against other established antibiotics. Research examined outcomes related to physical discomfort and inflammatory states, monitoring measurements of symptom changes during the study period. Findings describe patterns observed in the studies related to measured bacteriological status.

Evidence for Use in Acute Otitis Media (Middle Ear Infection)

Cefuroxime was studied for the management of acute otitis media (AOM), largely through multicenter, randomized trials focused on pediatric outpatients. Studies monitored outcomes related to acute or disruptive episodes, including clinical status and rates of status change or recurrence within a short follow-up window. The research so far indicates that studies reported measurements of status and how symptoms were assessed in the observed pediatric populations.


Evidence for Use in Early Lyme Disease (Erythema Migrans)

Research explored Cefuroxime in studies investigating early, localized Lyme disease, specifically the erythema migrans rash. Studies included randomized comparison trials and monitored outcomes related to daily functioning over defined time intervals, with follow-up durations typically extending up to six months or even a year post-study entry. Studies reported measurements of the characteristic rash status following entry into the study observation period.


What is Still Uncertain in the Research Landscape

Evidence contributes to the broader evidence landscape, yet several areas remain where research is ongoing or still needed. Follow-up durations were limited across most indications, leading to a general lack of information regarding long-term effects or the durability of symptom patterns over many months or years. Comparative evidence is lacking in some areas, as much of the historical research focused on equivalence testing. Finally, evidence quality varies across studies, and data are still emerging to address the impact of increasing antibiotic resistance on the treatment of common infections.

Key Studies & References

  1. Label: CEFUROXIME AXETIL tablet (FDA Drug Label)
  2. Clinical comparison of cefuroxime axetil suspension and amoxicillin/clavulanate suspension in the treatment of pediatric patients with acute otitis media with effusion
  3. IDSA/AAN/ACR 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease
  4. Cefuroxime - StatPearls - NCBI Bookshelf (Review of Indications)

Frequently Asked Questions (FAQ)

Common questions about Цефутил (FAQ)


Q: Are there known issues with older adults using Цефутил?

Older adults may be more likely to have reduced kidney function, which is the primary route for drug elimination. Regulatory documents indicate that careful dose selection and monitoring are important when Cefuroxime is administered to older adults with known or suspected kidney impairment.

Q: Where can official research on Цефутил's effectiveness be found?

The clinical studies that support the drug’s use and effectiveness are summarized in the Clinical Studies section of the official prescribing information documents. These regulatory documents, such as the FDA label or EMA Summary of Product Characteristics (SmPC), describe the key trials that led to the drug's approval.

Q: Is Цефутил used for short-term issues only, or can it be used long-term?

Cefuroxime is intended for the short-term treatment of acute bacterial infections. Official administration guidelines typically specify defined, short-term treatment durations. Clinical research has primarily examined short-term use, and regulatory information lacks data regarding chronic, long-term use.

Q: What are the documented signs of a serious allergic reaction to Цефутил?

Serious allergic reactions, such as anaphylaxis, are rare but clinically significant events documented in the safety profile. Documented signs may include swelling of the face, lips, or tongue, trouble breathing, or the appearance of a severe, blistering skin rash.

Q: What are the general conditions under which Цефутил is considered appropriate for children?

Cefuroxime is approved for use in pediatric patients starting from 3 months of age. It is used for the treatment of specific bacterial infections, including acute otitis media, pharyngitis, tonsillitis, and various respiratory and skin infections.

Q: Does Цефутил typically cause fatigue or sleepiness?

According to official product information, dizziness and headache are commonly reported side effects. Sleepiness, or somnolence, is also a documented side effect but is reported less frequently.

Q: How long does it usually take to feel the effects of Цефутил after starting it?

The drug begins to reach maximum concentration in the blood within approximately one hour after administration by injection. The time it takes for an individual to notice improvement in their symptoms depends on the specific infection being treated and how their body responds.

Q: How long does Цефутил remain in the body after the last use?

Cefuroxime has a short half-life of approximately 80 minutes. The medicine is primarily eliminated from the body by the kidneys, with most of the drug typically being excreted within 8 hours after administration.

Q: Are there any common over-the-counter pain relievers that interact with Цефутил?

Official drug interaction data does not specifically list common non-prescription pain relievers (such as ibuprofen or acetaminophen) as major interactive agents with Cefuroxime. The full list of known interactions is available in the official prescribing information.

Q: Is Цефутил available in a generic version?

The active ingredient in Цефутил is Cefuroxime, and this substance is available under various generic and brand names globally. Cefuroxime is the internationally recognized generic name for the drug.

Q: Does Цефутил interact with common dietary supplements like iron or magnesium?

Magnesium, when contained in antacid products, can reduce the absorption and effectiveness of Cefuroxime. Regulatory information notes that the timing of administration for all supplements may need consideration to prevent interference with the drug's absorption.

Q: Are there any foods or drinks that should be strictly avoided when using Цефутил?

Official labeling notes that the oral suspension form must be taken with food to ensure proper absorption of the medicine. The regulatory information does not require any specific foods or drinks to be strictly avoided.

Q: Is it possible to use Цефутил past the expiration date listed on the package?

No. The expiration date is established by the manufacturer to guarantee the drug's full potency and safety. Regulatory guidance requires that any expired or unused medicine be properly discarded and are intended to be discarded, not consumed.

Q: Is Цефутил known to cause issues with blood sugar levels?

Cefuroxime is not known to directly alter a person's blood sugar levels. However, official drug interaction data warns that it can cause false results with certain copper reduction tests used to check for glucose (sugar) in the urine.

Q: Are there specific warnings about driving or operating machinery while using Цефутил?

Due to the potential for common side effects like dizziness, official warnings describe the need for caution when performing activities that require alertness. This includes driving or operating machinery until the patient knows how the medicine affects them.

Q: What evidence exists for the use of Цефутил in individuals over 65?

Pharmacokinetic studies summarized in regulatory documents indicate that the way the body handles Cefuroxime (absorption and elimination) is similar between older adults and younger adults, provided their kidney function is equivalent.

Q: Does Цефутил carry a risk of causing dependency or addiction?

Cefuroxime is an antibiotic that is not classified as a controlled substance. Official regulatory documents do not list any risk of dependency or addiction associated with its use.

Q: What is the significance of the different dosage strengths of Цефутил mentioned in official documents?

Different strengths exist because the required dose of Cefuroxime varies depending on the type and severity of the bacterial infection being treated. The specific route of administration, such as oral versus injection, also determines the dose.

Q: Is Цефутил ever used in a preventative way for certain procedures?

Yes, the injectable form of Cefuroxime is formally indicated for use as surgical prophylaxis. This means it is used in certain situations to help prevent a bacterial infection from developing during or immediately after an operation.

Q: What official sources describe the full list of potential interactions for Цефутил?

The full, comprehensive list of potential drug interactions is contained within the official regulatory documents, such as the U.S. FDA Prescribing Information or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC). These are the authoritative sources for drug data.

How should Цефутил be stored and disposed of?

Storage and Disposal of Cefuroxime

Storage Requirements

Cefuroxime axetil tablets must be stored at Controlled Room Temperature, which is typically 20 C to 25 C. The dry powder for the oral suspension should be stored between 15 C and 30 C. Once the oral suspension is mixed, it can be kept refrigerated or at room temperature, but it must be used within 10 days and must not be frozen. The powder for injection requires storage protected from light.

Handling and Disposal

All forms of this medicine must be kept out of the sight and reach of children. Unused or expired medicine should not be flushed down the toilet or poured into a drain. The recommended disposal method is to use a community drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance, placed in a sealed bag, and disposed of in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цефутил found in:

A-Z Index: